Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Adamas Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Adamas Pharmaceuticals shares (ADMS) are listed on the NASDAQ and all prices are listed in US Dollars. Adamas Pharmaceuticals employs 138 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.05|
|52-week range||$2.96 - $9.15|
|50-day moving average||$5.71|
|200-day moving average||$5.21|
|Wall St. target price||$7.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.60|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-16)||N/A|
|1 month (2021-09-27)||55.41%|
|3 months (2021-07-27)||67.71%|
|6 months (2021-04-27)||35.07%|
|1 year (2020-10-26)||130.66%|
|2 years (2019-10-25)||104.83%|
|3 years (2018-10-26)||17.2|
|5 years (2016-10-26)||14.35|
|Revenue TTM||$82.5 million|
|Gross profit TTM||$72.4 million|
|Return on assets TTM||-16.4%|
|Return on equity TTM||0%|
|Market capitalisation||$366 million|
TTM: trailing 12 months
There are currently 2.4 million Adamas Pharmaceuticals shares held short by investors – that's known as Adamas Pharmaceuticals's "short interest". This figure is 5.9% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting Adamas Pharmaceuticals shares can be evaluated.
Adamas Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Adamas Pharmaceuticals shares currently shorted divided by the average quantity of Adamas Pharmaceuticals shares traded daily (recently around 151868.27231856). Adamas Pharmaceuticals's SIR currently stands at 15.57. In other words for every 100,000 Adamas Pharmaceuticals shares traded daily on the market, roughly 15570 shares are currently held short.
However Adamas Pharmaceuticals's short interest can also be evaluated against the total number of Adamas Pharmaceuticals shares, or, against the total number of tradable Adamas Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adamas Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Adamas Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0582% of the tradable shares (for every 100,000 tradable Adamas Pharmaceuticals shares, roughly 58 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Adamas Pharmaceuticals.
Find out more about how you can short Adamas Pharmaceuticals stock.
We're not expecting Adamas Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Adamas Pharmaceuticals's shares have ranged in value from as little as $2.96 up to $9.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adamas Pharmaceuticals's is 2.6042. This would suggest that Adamas Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.